
Opinion|Videos|March 28, 2024
BESPOKE CRC: The Impact of ctDNA-Guided Therapy in CRC
Focusing on the BESPOKE CRC study, John H. Strickler, MD, reviews recent updates presented at ASGO GI 2024 and discusses subset analyses from the trial.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
4
Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma
5


























































